Pfizer Wins U.S. Ruling to Block Generic Lyrica Until 2018
This article is for subscribers only.
Pfizer Inc., the world’s biggest drugmaker, won a court ruling that will block generic versions of its No. 1 product, Lyrica, in the U.S. until December 2018.
Teva Pharmaceutical Industries Ltd., Actavis Plc and Lupin Ltd. are among the generic-drug makers that would infringe a valid patent on the pain medicine, the U.S. Court of Appeals for the Federal Circuit in Washington said in an opinion today on its website. The other generic-drug makers in the case were Sun Pharmaceutical Industries Ltd., Wockhardt Ltd. and Mylan Inc.